RBC Capital maintained a Sector Perform rating on Mylan (NASDAQ: MYL), and cut the price target to $60.00 (from $64.00) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst PT Change

Perrigo (PRGO) Comments on Mylan (MYL) Presentation; Says it Appeared UnconvincingOctober 30, 2015 3:39 PM Perrigo Comments On Mylan's PresentationOctober 30, 2015 3:38 PM Guggenheim Sidelined on Mylan (MYL) Until More Clarity on M&A Strategy, FY18 Expectations is OfferedOctober 30, 2015 11:28 AM Mylan Appoints Ranjan Ray Chaudhuri as Global Commercial Lead for Mylan's Over-the-Counter BusinessOctober 30, 2015 7:15 AM Mylan (MYL) Tops Q3 EPS by 5c; Sees FY15 EPS at High End of OutlookOctober 30, 2015 7:02 AM Mylan Third Quarter 2015 Constant Currency Adjusted Total Revenues Increase 36% and Adjusted Diluted EPS Increases 23% to $1.43October 30, 2015 7:00 AM Mylan (MYL) Announces U.S. Court Denial of Perrigo's (PRFO) Preliminary Injunction RequestOctober 30, 2015 6:46 AM U.S. District Court Denies Perrigo's Motion for Preliminary Injunction Related to Certain Mylan DisclosuresOctober 30, 2015 6:45 AM Trading Radar for 10/30: ExxonMobil (XOM), Seagate (STX), Newell Rubbermaid (NWL), Wayfair (W) ReportOctober 29, 2015 2:16 PM Mylan Confirms Availability of EpiPen® (epinephrine injection) Auto-Injector for U.S. Patients Affected by Sanofi's Auvi-Q® (epinephrine injection, USP) RecallOctober 29, 2015 1:23 PM